LACTOLOGY FOUNDATION

ATC class A02BD comprises fixed oral combination products used for eradication of Helicobacter pylori, typically containing a proton pump inhibitor (PPI) plus two antibiotics; during lactation their risk profile is driven by the most toxic component of each regimen and by the cumulative gastrointestinal and microbiome impact on the breastfed infant.

Pharmacological overview

A02BD products are fixed combination packs indicated for H. pylori eradication in peptic ulcer disease and related conditions, each containing a PPI with two antibacterial agents.
Common PPIs in this class include omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole and the potassium‑competitive acid blocker vonoprazan.
Antibiotics most frequently co‑packaged are amoxicillin, clarithromycin, metronidazole, tetracycline, tinidazole, levofloxacin, rifabutin and bismuth salts (as a topical antimicrobial/antisecretory cofactor).
Standard “triple” therapy consists of a PPI twice daily plus two antibiotics for 7–14 days, while quadruple regimens add bismuth or a fourth antibiotic to overcome resistance and improve eradication rates beyond 90% in optimized protocols.

Representative A02BD combinations

(The broader index also includes lansoprazole + clarithromycin + tinidazole, PPI + amoxicillin + levofloxacin, rabeprazole‑based and vonoprazan‑based packs, and rifabutin‑containing salvage regimens, all sharing similar conceptual toxicological and lactational considerations.)

General toxicological considerations

These regimens combine agents that act systemically (antibiotics) with gastric‑restricted acid suppression, so systemic toxicity is mostly driven by the antibacterials.
PPIs have a relatively favorable acute toxicity profile but can alter gastric pH, mineral absorption, and microbiota; in short eradication courses this is rarely clinically significant in adults, though theoretical concerns exist about long‑term use.
Antibiotics used (amoxicillin, clarithromycin, metronidazole, tetracycline, tinidazole, levofloxacin, rifabutin) carry class‑specific risks: hypersensitivity and rash (beta‑lactams), QT prolongation and drug interactions (macrolides, fluoroquinolones), neurotoxicity and mutagenicity debate (nitroimidazoles), and teeth/bone toxicity (tetracyclines).
Because multiple antibiotics are co‑administered, there is an additive burden on the gut microbiome, with a real risk of antibiotic‑associated diarrhoea and Clostridioides difficile overgrowth, particularly in vulnerable adults; this also has implications for the infant’s microbiome when the mother is breastfeeding.
The fixed combinations limit dose flexibility; thus, in patients with prior severe allergy, significant cardiac disease, hepatic impairment or prior C. difficile, selection of the regimen must prioritize the least toxic constituent profile and may require non‑standard tailoring outside A02BD packs.

Pregnancy and lactation risk – general principles

For A02BD combinations the overall pregnancy and lactation risk is determined by the single most hazardous component plus potential synergy of adverse effects (e.g. combined diarrhoeagenic and dysbiotic impact).
In pregnancy, some components (tetracyclines, fluoroquinolones, rifabutin) are relatively contraindicated because of established or suspected fetal toxicity, whereas others (amoxicillin, certain PPIs) are generally considered acceptable when clearly indicated.
During lactation, the key determinants are drug transfer into breast milk, oral bioavailability to the infant, and the infant’s maturity and comorbidities; short courses are usually lower risk than prolonged exposure.
Because H. pylori infection is often chronic and largely asymptomatic for years, eradication during breastfeeding is not usually urgent; postponement is often recommended unless there is a compelling indication (e.g. high‑risk ulcer disease, gastric MALT lymphoma).
In line with your own Bulgarian page, a conservative toxicological‑lactological approach considers H. pylori eradication in lactating women generally undesirable, with rare exceptions where maternal benefit is dramatic and alternatives are lacking.

Lactational profile of key components

Proton pump inhibitors and vonoprazan

PPIs such as omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole are weak bases with relatively high protein binding and short plasma half‑lives, resulting in low expected passage into breast milk.
Clinical data in breastfeeding are limited, but extrapolation from pharmacokinetics and post‑marketing experience suggests a low risk of clinically relevant infant exposure, particularly with standard 7–14‑day courses.
Vonoprazan, a more potent acid blocker, lacks robust lactation data; given its higher and more sustained acid suppression and different binding profile, caution is advisable and it should generally be avoided during breastfeeding until more data accrue.

Beta‑lactams (amoxicillin)

Amoxicillin is widely considered compatible with breastfeeding, with minimal adverse effects reported in infants and extensive experience supporting its use.
Milk concentrations are low, and occasional infant diarrhoea or candidiasis represent the main observed issues, typically mild and self‑limiting.
From a toxicological‑lactological standpoint, amoxicillin does not usually represent the limiting factor in A02BD risk categorization and is generally acceptable where eradication is deemed necessary.

Macrolides (clarithromycin)

Macrolides overall are considered usable in breastfeeding with infant monitoring, though they can alter gut flora and may cause mild gastrointestinal symptoms.
Specialist sources state that all clarithromycin formulations, including intravenous therapy, may be used with caution during breastfeeding, implying relatively low milk transfer and manageable risk.
However, clarithromycin has significant CYP3A4‑mediated interaction potential and is associated with QT prolongation, so maternal cardiometabolic profile and concomitant drugs must be carefully assessed when part of an A02BD combination.

Nitroimidazoles (metronidazole, tinidazole)

Oral and parenteral metronidazole passes into breast milk in moderate amounts but short courses are considered compatible with breastfeeding, with infant monitoring recommended for diarrhoea or candidiasis.
Consensus statements note no established mutagenic or carcinogenic risk to infants exposed via breast milk at therapeutic doses, mitigating earlier theoretical concerns.
Tinidazole, a related nitroimidazole often used in clarithromycin‑tinidazole‑PPI packs, has less lactation data; its longer half‑life suggests more prolonged infant exposure, so avoidance or temporary breastfeeding interruption is commonly advised when high doses are used.

Tetracyclines

Tetracycline in short courses yields low milk concentrations and limited infant absorption; nevertheless, there are longstanding theoretical concerns about effects on developing teeth and bone, particularly with repeated or prolonged exposure.
Because safer alternatives exist for most maternal infections, tetracycline‑containing H. pylori regimens are rarely first choice during breastfeeding; from a toxicology‑lactation perspective they are generally discouraged.

Fluoroquinolones and rifabutin

Levofloxacin has low oral bioavailability in milk‑exposed infants and is increasingly regarded as acceptable in breastfeeding with monitoring, though long‑term safety is less well characterized and cartilage toxicity concerns persist.
Rifabutin‑based regimens are used as salvage therapy; rifabutin is a potent antimycobacterial with limited lactation data, potential for neutropenia and uveitis, and significant interaction profile, making it a high‑caution component in breastfeeding women.
In salvage A02BD combinations with rifabutin, the toxicological‑lactological category is dominated by rifabutin risk, and postponement of eradication or temporary cessation of breastfeeding should be strongly considered.

Practical toxicology–lactology positioning for A02BD

In clinical practice and within your own lactology foundation framework, overall risk assessment for A02BD regimens in breastfeeding focuses on three axes: the most toxic antibiotic, cumulative microbiome disruption, and the non‑urgency of eradication.
Most individual components (amoxicillin, clarithromycin, metronidazole, standard PPIs) can be used during lactation for short courses with infant monitoring, but when combined, they simultaneously perturb maternal and infant microbiota, increase diarrhoea risk, and add theoretical mutagenic/carcinogenic and cardiac safety concerns.
Therefore, routine H. pylori eradication in breastfeeding women is generally not recommended; the task is described in your page as “both difficult and easy”, with the practical rule that the highest individual toxico‑lactational category in the combination determines the overall rating and typically leads to postponement.
Exceptions may be justified in cases such as gastric MALT lymphoma, severe recurrent bleeding ulcers or documented high‑grade dysplasia, where maternal benefit is substantial and may outweigh the infant’s theoretical risk, provided that a relatively safer combination (e.g. PPI + amoxicillin + metronidazole) is chosen and breastfeeding is closely monitored or temporarily suspended.

Example clinical scenario

A lactating woman with mild dyspeptic symptoms and H. pylori positivity but no ulcer or bleeding does not usually require immediate eradication; symptom control with PPI monotherapy and non‑pharmacological measures is preferred until breastfeeding is completed.
Conversely, a breastfeeding patient with gastric MALT lymphoma and H. pylori positivity may benefit markedly from eradication therapy, which can induce lymphoma remission, so a carefully selected triple therapy and individualized breastfeeding plan may be considered despite the higher toxicological‑lactological risk.